Drug intelligence / Profile preview

carvedilol + alverine

Development stage
Unknown
Lead developer
Roche
Modality
Small Molecules
Administration
Oral
01

Overview

Carvedilol + alverine is a combination of two small molecule drugs, each with distinct mechanisms and indications. Carvedilol is a non-selective beta-adrenergic antagonist (beta-blocker) with additional alpha-1 adrenergic blocking activity, primarily used to treat mild to severe chronic heart failure, hypertension, and left ventricular dysfunction following myocardial infarction[1][3][5]. It works by slowing the heart rate and relaxing blood vessels, thereby reducing blood pressure and cardiac workload. Alverine is a smooth muscle relaxant indicated for the relief of cramps or spasms in the stomach and intestines, commonly used in conditions such as irritable bowel syndrome (IBS) and other gastrointestinal disorders[9]. It acts directly on gut smooth muscle to prevent spasms that cause pain or discomfort. The combination of these agents does not represent an established fixed-dose product but would theoretically combine cardiovascular effects (from carvedilol) with antispasmodic effects on the gastrointestinal tract (from alverine).

02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)5-HT2 (5-HT2 receptor family)DRD2 (Dopamine D2 Receptor)ADRB1 (β1)ADRA1A (α1A)ADRB2 (β2)ADRA2A (α2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on carvedilol + alverine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on carvedilol + alverine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call